News

People with more severe myasthenia gravis (MG) have a greater likelihood of experiencing episodes of exacerbation, when symptoms worsen or reappear, and may need more medical care, according to the findings of a new study. The study also suggested that personalized treatment for these MG patients may ease the…

Myasthenia gravis (MG) may be more likely to begin manifesting in the summer, with the onset of symptoms more common in hotter weather, according to a new study by researchers in Italy. The team theorized that the increased incidence of MG may occur because temperatures at that time of…

A 39-year-old woman with severe myasthenia gravis (MG) associated with a thymoma, a thymus tumor, responded favorably to treatment with Ultomiris (ravulizumab), according to a case study from clinicians in Greece. The treatment successfully managed the woman’s rapidly evolving symptoms in the acute setting. The patient later underwent…

The COVID-19 pandemic caused emotional challenges for many people with myasthenia gravis (MG) in Australia, but how well their disease was treated or how well  their symptoms were kept under control weren’t affected, a survey study finds. “As we continue to live with COVID-19, clinicians should consider its various…

Tofacitinib, an approved medication for some types of inflammatory arthritis and inflammatory bowel disease, may also help treat myasthenia gravis (MG), a new study done in an animal model and cell samples suggests. Treatment with tofacitinib was found to ease muscle weakness and weight loss in a rat model…

Top-line results from a Phase 3 clinical trial of batoclimab in people with generalized myasthenia gravis (gMG) are expected by the end of March, Roivant, which is developing the antibody therapy through its subsidiary Immunovant, reported. The company said that trial findings will inform further decisions regarding next…

People with myasthenia gravis (MG) face a mean annual healthcare cost of nearly $16,000, according to a survey of MG patients and their caregivers. Medications and treatments accounted for most out-of-pocket expenses (27%), followed by insurance premiums (20%), diagnosis (15%), and caregiving assistance (14%). “Disseminating the findings of this…

People newly diagnosed with myasthenia gravis (MG) in England experience a high disease burden, with about two-thirds having at least one exacerbation, or an episode of disease worsening, and approximately half having one MG-related hospitalization. That’s according to a new study led by researchers from the pharmaceutical company…

Enspryng (satralizumab), tested by Chugai Pharmaceutical as a treatment for generalized myasthenia gravis (gMG), eased disease symptoms and made daily life easier when used in addition to standard of care therapy over six months, but its clinical benefit was somewhat limited. These data from LUMINESCE (NCT04963270), a…

People with myasthenia gravis (MG) have a higher risk of developing cancer in organs other than the thymus, particularly in the skin and gastrointestinal tract, than people without the disease, according to a study. The incidence of such cancers tended to be higher in the five years before and…